Advertisement
Home »

Novel Agent VTX002 Shows Promise for Patients With UC in Phase 2 Study

Mar 01, 2024

REFERENCES & ADDITIONAL READING

Sands B, et al. Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active ulcerative colitis: results from a randomized, double-blind, placebo-controlled, phase 2 trial. OP03, 19th Congress of ECCO, February 21–24, 2024, Stockholm, Sweden.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement